New combo for tough kidney cancer shows promise but study halted early
NCT ID NCT04904302
First seen Nov 20, 2025 · Last updated Apr 30, 2026 · Updated 16 times
Summary
This study tested a combination of two drugs, sitravatinib and nivolumab, in 15 adults with advanced clear cell kidney cancer that had worsened after previous treatments. The goal was to see if the combination could shrink tumors or slow the disease. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV RENAL CELL CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Indiana University Hospital / IU Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.